Li Kemin, Zeng Jing, Zhang Mengpei, Yin Rutie, Li Zhengyu
The Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, China.
Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China.
Front Oncol. 2022 Jun 30;12:807748. doi: 10.3389/fonc.2022.807748. eCollection 2022.
To study the correlation between mutation status and the risk of adverse reactions in patients with ovarian cancer.
A real-world study was conducted at the largest gynecological oncology center in western China, the West China Second University Hospital of Sichuan University. The research subjects were patients diagnosed with ovarian cancer who were initially treated in our hospital from January 2016 to January 2020 and had their gene status evaluated. Multivariate Cox analysis was conducted to investigate the correlation between the mutation status and adverse reactions in ovarian cancer patients during initial treatment.
A total of 349 ovarian cancer patients were enrolled, including 79 patients with pathogenic variants, resulting in a pathogenic mutation rate of 22.6%. Among these 79 patients, 57 had variants and 22 had variants, yielding a pathogenic mutation rate of 16.3% and 6.3%, respectively. Multivariate COX analysis revealed that pathogenic variants were not related to the risk of adverse reactions, such as myelosuppression and allergies to chemotherapy drugs (>0.05), during the initial treatment of ovarian cancer.
variants did not increase the risk of adverse reactions, such as myelosuppression and allergies to chemotherapy drugs, in ovarian cancer patients during initial treatment.
研究卵巢癌患者的基因突变状态与不良反应风险之间的相关性。
在我国西部最大的妇科肿瘤中心——四川大学华西第二医院开展一项真实世界研究。研究对象为2016年1月至2020年1月在我院初治且进行了基因状态评估的卵巢癌患者。采用多因素Cox分析研究卵巢癌患者初治期间基因突变状态与不良反应之间的相关性。
共纳入349例卵巢癌患者，其中79例存在致病性变异，致病性突变率为22.6%。在这79例患者中，57例为 变异，22例为 变异，致病性突变率分别为16.3%和6.3%。多因素COX分析显示，致病性 变异与卵巢癌初治期间骨髓抑制、化疗药物过敏等不良反应风险无关（>0.05）。
变异未增加卵巢癌患者初治期间骨髓抑制、化疗药物过敏等不良反应的风险。
